The U.S. Food and Drug Administration today approved a drug to treat women experiencing pain during sexual intercourse. The drug, Osphena, is approved for a type of pain known as dyspareunia (pain during sexual intercourse), which is a symptom of vulvar and vaginal atrophy due to menopause.
Dyspareunia is associated with declining levels of estrogen hormones during menopause. Osphena, known chemically as ospemifene, is a pill that acts like estrogen on vaginal tissues to make them thicker and less fragile, resulting in a reduction in pain associated with intercourse.
J. Kyle Mathews, MD
Plano OB GYN Associates